low-molecular weight heparin

low-molecular weight heparin

Enoxaparin/Lovenox®, dalteparin, fraxiparin Pharmacology A heparin with advantages over unfractionated heparin, which blocks thrombosis earlier in the coagulation cascade than conventional heparin by inhibiting factor Xa; it less likely to cause thrombocytopenia or thrombotic thrombocytopenia syndrome Indications DVT. See Deep vein thrombosis.
References in periodicals archive ?
Low-molecular Weight Heparin (LMWH) is increasingly being used in emergency department and during surgery procedures in the hospitals as compared to Unfractioned Heparin (UFH), owing to increasing medical infrastructure along with surgical procedures.
Secondary research includes information collected from various sources, by study of company websites, annual reports, stock analysis presentations, press releases, and various national and international databases.On the basis of product type global heparin market is segmented into unfractionated heparin (UFH), low-molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH).
Methods: Two hundred and sixty patients with cerebral infarction, acute myocardial infarction or pulmonary embolism who underwent subcutaneous injection of low-molecular weight heparin in the hospital between December 2015 and December 2016 were selected.
Comparison of low-molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
Although low-molecular weight heparin (LMWH) and low dose aspirin (LDA) are generally considered safe, 10, 11 there is no direct evidence of their efficacy for miscarriage prevention.
d--Enoxaparin is a low-molecular weight heparin. Although enoxaparin and other LMWHs have a lower risk of HIT than unfractionated heparin, they still may precipitate an episode of HIT.
Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: A multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP).
Reportedly, in preclinical studies, ISIS-FXIRx demonstrated potent antithrombotic activity with no increase in bleeding compared with standard anti-clotting agents, including low-molecular weight heparin, warfarin and Factor Xa inhibitors, all of which increased bleeding.
In their study, the researchers administered a fixed dose of plain heparin by syringe to half of the 708 volunteers and a low-molecular weight heparin, also by syringe, to the others.
Given that many patients are now sent home with low-molecular weight heparin, he said, interventional radiologists often are not called until 2 and 3 weeks later in difficult cases.
Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 2003; 349:146-153.

Full browser ?